ClinicalTrials.Veeva

Menu

Predictors of Heart Failure After ST-segment Elevation Myocardial Infarction (HF-EXPRESS)

D

Dr. Nafiz Korez Sincan State Hospital

Status

Unknown

Conditions

Heart Failure and ST Elevation Myocardial Infarction

Treatments

Procedure: Percutanous coronary intervention

Study type

Observational

Funder types

Other

Identifiers

NCT02650934
114S309

Details and patient eligibility

About

Objective: The purpose of this project is to study the post miyocardial infaction (MI) damage and subsequently developed post-infarct cardiac repair process on the basis of cellular, molecular and imaging techniques. Besides this, whole genomesequencing and analysis (GWAS) will be performed to determine common varying genetic loci in order to anticipate whetherthese findings and its related pathways would be the predictors of adverse remodeling after MI or not.

Full description

A brief description of the issue and the original value of the subject: Epidemiological studies show a clear increase ininfarct-related complications due to increased survival after MI and aging population. Heart failure is the most prevalent complication after MI, which has reached epidemic proportions in western societies. For the period between 2010 and 2030,according to projections made in developed countries, about 10% increment in all cardiovascular disease is being predictedhowever increment in heart failure (HF) would be such a dramatic figure which is about 25%. HF is an increasing burden tosociety and healthcare systems, since its prevalence and incidence is dramatically increasing. There has not been aprospective study that assesses the exact cellular and geometric course after MI in human. This study will allow us tounderstand the behavior of cells involved in cardiac repair after MI. In addition, it will show us the exact functional andgeometric course after MI. Finally, the current study will also provide novel diagnostic and therapeutic targets via genomic andproteomic studies. All together, we envision to find new efficient ways to identify/treat patients at risk to develop HF after MI.

Enrollment

312 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18-80 years old patients with myocardial infarction in the first 12 hours TIMI 3 flow following PCI

Exclusion criteria

Right ventiricular myocardial infarction Cardiogenic shock History of CABG, PCI or valvular disease History of Cardiomyopathy severe LV hypertrophy No reflow after PCI Chronic kidney disease (GFR<60) Systemic inflammatory disease

Trial design

312 participants in 2 patient groups

Adverse remodelling
Description:
EF below 40% following MI and remain below 40% after reperfusion
Treatment:
Procedure: Percutanous coronary intervention
not adverse remodelling
Description:
EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
Treatment:
Procedure: Percutanous coronary intervention

Trial contacts and locations

1

Loading...

Central trial contact

Ferhat Eyyupkoca, MD; Ahmet G Ertem, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems